{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Regimen&page=40", "query": { "intervention": "Control Regimen", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 1567, "total_pages": 157, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Regimen&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Regimen&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T12:57:28.973Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04156464", "title": "Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Alcohol Withdrawal", "Alcohol Withdrawal Delirium" ], "interventions": [ { "name": "Phenobarbital", "type": "DRUG" }, { "name": "Lorazepam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSF Healthcare System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2020-07-06", "completion_date": "2022-03-01", "has_results": false, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 1, "location_summary": "Peoria, Illinois", "locations": [ { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04156464" }, { "nct_id": "NCT04816643", "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection, COVID-19" ], "interventions": [ { "name": "Biological/Vaccine: BNT162b2 10mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 20mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 30mcg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Biological/Vaccine: BNT162b2 3mcg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "15 Years", "sex": "ALL", "summary": "6 Months to 15 Years" }, "enrollment_count": 11837, "start_date": "2021-03-24", "completion_date": "2023-12-08", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04816643" }, { "nct_id": "NCT02137837", "title": "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo - Anastrozole", "type": "DRUG" }, { "name": "Placebo - Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2014-05", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 223, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02137837" }, { "nct_id": "NCT04695977", "title": "CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Melanoma", "Advanced Melanoma", "Metastatic Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "CMP-001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-02-24", "completion_date": "2024-07-22", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04695977" }, { "nct_id": "NCT04429022", "title": "Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Paracervical block with ropivacaine", "type": "PROCEDURE" }, { "name": "Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites", "type": "PROCEDURE" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "State University of New York at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "25 Years to 90 Years · Female only" }, "enrollment_count": 68, "start_date": "2020-11-24", "completion_date": "2022-05-31", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 1, "location_summary": "Williamsville, New York", "locations": [ { "city": "Williamsville", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04429022" }, { "nct_id": "NCT04419857", "title": "A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neonatal Abstinence Syndrome" ], "interventions": [ { "name": "High-calorie formula", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 39, "start_date": "2020-12-04", "completion_date": "2025-05-01", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419857" }, { "nct_id": "NCT01358877", "title": "A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4804, "start_date": "2011-11-08", "completion_date": "2024-11-28", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 114, "location_summary": "Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Everett", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358877" }, { "nct_id": "NCT03971097", "title": "The Effect of Self-Forgiveness on Self-Stigma in Addiction.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Substance Use Disorders", "Opiate Dependence", "Opiate Withdrawal Syndrome", "Opioid-use Disorder", "Alcohol Withdrawal", "Alcohol Abuse", "Alcohol Use Disorder", "Cocaine Abuse", "Cocaine Use Disorder", "Cocaine Withdrawal", "Benzodiazepine Abuse", "Benzodiazepine Dependence", "Substance Abuse", "Heroin Overdoses", "Heroin Withdrawal", "Heroin Abuse" ], "interventions": [ { "name": "Six Step Model of Self-Forgiveness", "type": "BEHAVIORAL" }, { "name": "Treatment as Usual (TAU)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2019-08-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 1, "location_summary": "McKeesport, Pennsylvania", "locations": [ { "city": "McKeesport", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03971097" }, { "nct_id": "NCT06077201", "title": "Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Valvular Heart Disease" ], "interventions": [ { "name": "HBCR hands-off", "type": "OTHER" }, { "name": "HBCR interactive", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-12-15", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06077201" }, { "nct_id": "NCT05041491", "title": "Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pre-diabetes" ], "interventions": [ { "name": "BREAK", "type": "BEHAVIORAL" }, { "name": "ONE", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 66, "start_date": "2021-11-30", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-11-01T12:57:28.973Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05041491" } ] }